Voyager Therapeutics (NASDAQ:VYGR) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR – Get Rating) in a report published on Thursday morning. The brokerage issued a buy rating on the stock.

Separately, Oppenheimer began coverage on shares of Voyager Therapeutics in a report on Thursday, March 9th. They issued an outperform rating and a $14.00 price target for the company.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $7.92 on Thursday. The company has a 50-day simple moving average of $8.22 and a 200-day simple moving average of $6.70. Voyager Therapeutics has a one year low of $4.61 and a one year high of $10.81.

Insider Transactions at Voyager Therapeutics

In related news, major shareholder Ecor1 Capital, Llc sold 456,000 shares of the company’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $7.67, for a total transaction of $3,497,520.00. Following the transaction, the insider now directly owns 4,297,907 shares of the company’s stock, valued at $32,964,946.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Ecor1 Capital, Llc sold 456,000 shares of the stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $7.67, for a total value of $3,497,520.00. Following the completion of the sale, the insider now directly owns 4,297,907 shares of the company’s stock, valued at $32,964,946.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Rock Ventures Iii L.P. Third sold 100,000 shares of the stock in a transaction that occurred on Friday, January 20th. The stock was sold at an average price of $9.15, for a total transaction of $915,000.00. Following the completion of the sale, the insider now directly owns 5,328,933 shares of the company’s stock, valued at $48,759,736.95. The disclosure for this sale can be found here. Insiders sold a total of 1,035,636 shares of company stock valued at $8,724,631 over the last quarter. Company insiders own 22.00% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC lifted its position in shares of Voyager Therapeutics by 32.4% in the third quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after purchasing an additional 832,000 shares in the last quarter. Hillsdale Investment Management Inc. raised its position in Voyager Therapeutics by 347.3% during the third quarter. Hillsdale Investment Management Inc. now owns 87,967 shares of the company’s stock valued at $521,000 after acquiring an additional 68,300 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Voyager Therapeutics by 11.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 37,788 shares of the company’s stock valued at $224,000 after acquiring an additional 3,933 shares in the last quarter. Bailard Inc. bought a new position in Voyager Therapeutics during the third quarter valued at approximately $171,000. Finally, Gamco Investors INC. ET AL bought a new position in Voyager Therapeutics during the fourth quarter valued at approximately $73,000. 59.58% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.